Formulation development serves as a vital bridge between a drug substance and a drug product that will remain stable and ...

Antibody-drug conjugates (ADCs) are promising biotherapeutic candidates that combine highly potent cytotoxic drugs with monoclonal antibodies (mAbs) for targeted drug delivery in the treatment of ...

Appropriate use of sound science applied at critical junctures will improve efficiency in the high-wire act of drug development. Pharmaceutical companies walk a tightrope in early drug development.

LNPs continue to dominate the spotlight in biopharma with three landmark acquisitions in the past six months, AbbVie/Capstan Therapeutics, Eli Lilly and Co/Verve Therapeutics and Bristol Myers ...

In the last 10 years, there has been significant development in computer simulation of pharmaceutical materials, processes and product performance. Gradually, more mechanistically based models are ...

Embrace Technology Innovations to Optimise LNP Formulation, Alternative LNP Raw Materials, Process Control to Achieve Seamless Scale-Up, Compliance & Cost Effectiveness The inaugural LNP Formulation & ...

In this Pharma Matters Q&A, Anshul Gupte of PCI Pharma Services discusses investments and opportunities in sterile ...

The timely Viral Vector Formulation and Process Development Summit Europe is the only definitive, end-to-end platform, uniting 60+ experts across up-and downstream process development, formulation, ...

The stability of lisinopril in an extemporaneously prepared suspension stored at or below 25 °C for 28 days under ambient light exposure was studied. A formulation of 1-mg/mL oral suspension was ...

After the suspension was prepared, the bottles were shaken individually for 30, 60, or 90 seconds. Table 1 summarizes the effect of shaking time on the solubility of lisinopril. The entire content of ...